Watercolor painting of a thoughtful woman with brown hair resting her chin on her hand, wearing a blue cardigan.
Moving beyond frightening headlines toward informed, individualized care
ADHD care is often discussed in terms of concentration, productivity, and performance. Mortality research asks a more consequential question: How does living with ADHD intersect with long-term health and survival, and might treatment change those outcomes?
A systematic review and meta-analysis published on October 19, 2026, in JAMA Network Open brings this question into sharper focus. Across 19 studies, ADHD was associated with higher mortality from several causes, while ADHD medication use was associated with lower all-cause mortality among people with ADHD (Corrigan et al., 2026). These findings deserve attention, but they do not justify fatalistic predictions about people with ADHD or categorical claims that medication extends life.
The most useful organizing principle is prevention: taking potentially modifiable risks seriously while distinguishing population-level associations from individual prognosis.
What the New Review Actually Found
Corrigan et al. (2026) systematically searched six databases for research available through July 8, 2025. Their review included 19 studies with a combined reported sample of 15,920,970 participants, 36.1% of whom were female. The studies spanned multiple countries and age groups; this was not an exclusively adult-ADHD analysis.
Twelve studies contributed to quantitative meta-analyses, while the remaining seven were discussed narratively. Consequently, the headline sample size describes the overall review, not the number of participants contributing to every pooled estimate.
The researchers used random-effects models, which allow the underlying association to vary across studies rather than assuming that every population shares one identical effect.
Compared with people without ADHD, people with ADHD had a pooled all-cause mortality hazard ratio of 1.71, 95% confidence interval [1.31, 2.24]. This corresponds to a 71% higher mortality hazard during the studies’ observation periods. ADHD was also associated with an 89% higher hazard of death by suicide, HR = 1.89, 95% CI [1.21, 2.95], and a 55% higher hazard of death from unintentional or intentional injury, HR = 1.55, 95% CI [1.22, 2.00]. For natural-cause mortality, the association was smaller but remained statistically significant: HR = 1.27, 95% CI [1.16, 1.38], corresponding to a 27% higher hazard (Corrigan et al., 2026).
Among people with ADHD, medication use was associated with a 25% lower all-cause mortality hazard, HR = 0.75, 95% CI [0.64, 0.87]. This estimate came from three studies and compared people with ADHD using medication with those not using medication. It did not compare medicated people with ADHD against people without ADHD (Corrigan et al., 2026).
It is important to understand what these percentages actually mean. A 71% higher hazard does not mean that 71% of people with ADHD will die prematurely. Likewise, a 25% lower hazard does not mean that the likelihood of death decreases by 25 percentage points. Hazard ratios reflect the relative rate at which an event occurs over a period of follow-up. They do not tell us the actual probability that a particular individual will experience that event.
Relative Risk Is Not Individual Destiny
The absolute meaning of a relative association depends on the underlying event rate, the population, and the observation period. This is particularly important when discussing uncommon outcomes in younger populations.
Li et al. (2024) provide a useful example. In a Swedish nationwide observational study of 148,578 people with newly diagnosed ADHD, ages 6–64, the estimated two-year mortality risk was 39.1 per 10,000 people under a medication-initiation strategy versus 48.1 per 10,000 under a noninitiation strategy. The authors reported an adjusted risk difference of 8.9 fewer deaths per 10,000 people over two years. Medication initiation was associated with a lower all-cause mortality hazard, HR = 0.79, 95% CI [0.70, 0.88].
The relative figures help show why the findings matter at a population level, while the absolute figures put the results into perspective and help readers understand the actual size of the risk. Neither tells us what will happen to any one person.
Why Might ADHD Be Associated With Higher Mortality?
The review does not identify one causal mechanism. Instead, Corrigan et al. (2026) describe several plausible, interacting pathways: injury exposure, co-occurring psychiatric conditions, physical-health conditions, difficulties accessing or navigating health care, and broader social disadvantage. These are explanatory hypotheses informed by the literature, not mechanisms proven by the meta-analysis itself.
Injury and Everyday Safety
Differences in attention and impulse regulation may contribute to risk in situations such as driving or other safety-sensitive activities. Substance use and environmental demands may further complicate those relationships.
Importantly, an association between ADHD and injury-related mortality should not be translated into the stereotype that ADHDers are inherently reckless. The review emphasizes a multifactorial explanation rather than a single behavioral deficit (Corrigan et al., 2026).
Co-Occurring Mental-Health Conditions
The suicide finding requires particular care. Corrigan et al. (2026) discuss depression, anxiety, trauma-related conditions, substance use disorders, and experiences of exclusion or stigma as possible contributors.
The pooled association does not establish that ADHD independently explains every component of elevated suicide mortality. Nor does it mean that suicidality is inevitable for people with ADHD. It supports attention to mental health beyond core ADHD symptoms.
Physical Health and the Burden of Managing Care
Health care requires sustained administrative work: arranging appointments, obtaining prescriptions, following multistep instructions, and returning for monitoring. Corrigan et al. (2026) identify difficulties with organization, treatment adherence, and engagement with services as plausible contributors to adverse outcomes, alongside higher rates of some physical-health conditions and health-risk exposures.
This suggests a clinically important reframing: when health maintenance repeatedly breaks down, the relevant question is not simply whether someone understands what to do. It is also whether the care plan is realistically accessible and executable.
Does ADHD Medication Reduce Mortality?
The evidence is encouraging, but the causal question remains unresolved.
In Corrigan et al. (2026), the medication estimate came from only three studies. Medication use was associated with lower all-cause mortality, but the authors caution against interpreting this as proof of a causal protective effect. Treated and untreated groups may differ in health-care access, socioeconomic circumstances, ADHD severity, psychiatric comorbidity, and treatment adherence. Statistical adjustment cannot guarantee removal of all such differences.
These concerns can operate in different directions. Confounding by indication occurs when the reasons for receiving treatment, such as greater clinical severity, also relate to the outcome. Conversely, differences in access and engagement may favor treated groups if obtaining medication also reflects more consistent contact with health services. Unmeasured circumstances may affect both treatment continuity and mortality.
Consequently, the observed medication association may reflect medication effects, differences between groups, or a combination of both.
What the Swedish Medication Study Adds
Li et al. (2024) used a target trial emulation framework: an observational design that specifies treatment strategies and follow-up to approximate aspects of a hypothetical randomized trial. Medication initiation meant dispensing ADHD medication within three months of diagnosis. Although this approach strengthens the design, it does not create randomization or eliminate unmeasured confounding.
The association was clearest for deaths from unnatural causes, including unintentional injuries, suicide, and accidental poisonings: HR = 0.75, 95% CI [0.66, 0.86]. The estimate for natural-cause mortality was not statistically conclusive, HR = 0.86, 95% CI [0.71, 1.05] (Li et al., 2024).
That pattern is compatible with the hypothesis that treatment could influence pathways involving everyday safety and behavioral regulation. It does not demonstrate which pathway produced the association.
There is also an evidence-accounting issue: Li et al. (2024) was included in Corrigan et al.’s (2026) review. Discussing both papers illuminates the evidence, but they should not be counted as wholly independent confirmations. A meta-analysis synthesizes its contributing studies; it does not generate a new, separately observed treatment effect.
How Does This Connect With Research on ADHD and Life Expectancy?
O’Nions et al. (2025) examined an adult-only UK cohort using primary-care records. They compared 30,039 adults with diagnosed ADHD with 300,390 adults matched by age, sex, and primary-care practice. Using age-specific mortality rates and life-table methods, they estimated an apparent life-expectancy deficit of 6.78 years for males and 8.64 years for females with diagnosed ADHD.
Those estimates are striking, but their interpretation depends on who entered the study. Only approximately 0.32% of adults in the underlying cohort had a recorded ADHD diagnosis; far fewer than the estimated number of adults likely to have ADHD. Diagnosed participants therefore represented a selected subgroup, not the entire ADHD population (O’Nions et al., 2025).
Moreover, life-table estimates are statistical summaries constructed from observed mortality rates. They are not a countdown attached to an individual diagnosis.
This study, also included in Corrigan et al.’s (2026) review, supports concern about health inequalities among diagnosed adults. It does not justify telling an individual ADHDer that they will lose a specific number of years of life.
The Cardiovascular Counterpoint: Benefits and Risks Can Coexist
A responsible discussion cannot present lower observed mortality with medication while ignoring potential adverse outcomes.
Zhang et al. (2024) investigated long-term ADHD medication exposure and cardiovascular disease in a Swedish population of 278,027 individuals aged 6–64. In their case-control analysis, longer cumulative medication use was associated with higher odds of cardiovascular disease, particularly hypertension.
More than five years of use, compared with nonuse, was associated with an adjusted odds ratio of 1.23, 95% CI [1.12, 1.36], for cardiovascular disease and 1.80, 95% CI [1.55, 2.08], for hypertension. This study was also observational (Zhang et al., 2024).
These results do not necessarily contradict the mortality findings. Developing hypertension and dying from any cause are different outcomes. A treatment could plausibly improve some pathways while worsening others, and studies with different follow-up periods may capture different parts of that balance.
Nor can these estimates be subtracted from one another to calculate a net benefit. They involve different outcomes, statistical measures, exposure definitions, and populations.
The clinically defensible implication is individualized benefit–risk assessment and ongoing cardiovascular monitoring, not a blanket conclusion that medication is either uniformly protective or uniformly harmful (Zhang et al., 2024).
What Makes the Evidence Persuasive—and What Limits It?
The 2026 review’s strengths include its international scope, systematic search, separate examination of causes of death, and explicit consideration of medication. Nevertheless, the impressive total sample size should not obscure important limitations.
Substantial Heterogeneity
Between-study heterogeneity was very high for all-cause mortality, , suicide mortality, , and injury mortality, . Medication-related all-cause mortality showed more moderate heterogeneity, , while natural-cause mortality showed little detected heterogeneity (Corrigan et al., 2026).
These statistics indicate that variation between study estimates cannot be attributed solely to sampling error. The pooled hazard ratio is therefore best understood as an average across differing settings, not a universal constant applicable to every ADHDer.
Differences in Populations and Measurement
Studies varied in age, health-care context, ADHD identification, follow-up, and statistical adjustment. Eligibility extended beyond diagnosed ADHD to trait measures and polygenic risk scores. Most studies relied on diagnostic records, but these approaches do not identify identical populations.
Reliable subgroup analyses were not possible because study characteristics and reporting were too uneven (Corrigan et al., 2026). This limits the precision with which the findings can be applied to specific adult populations.
Limited Medication Evidence
Only three studies contributed to the pooled medication estimate. That finding is clinically relevant, but it is a considerably narrower evidence base than “nearly 16 million participants” might imply.
The analysis does not establish the mortality effect of a particular medication, dose, or treatment plan for a particular adult (Corrigan et al., 2026).
Representation and Review Procedures
Female participants constituted 36.1% of the overall sample. The authors also noted limitations in understanding outcomes across demographic groups.
In addition, although data extraction was conducted independently by two reviewers, study-quality assessment was completed by one reviewer, and only a subset of screening decisions received independent duplicate review. These procedural features warrant acknowledgment without invalidating the findings (Corrigan et al., 2026).
What This Means to ADHDers
1. These Findings Describe Groups, Not Your Future
You cannot derive your personal life expectancy from a pooled hazard ratio. The studies do not contain the information necessary to predict how long a particular reader will live.
The appropriate response is informed care, not an assumption that harm is inevitable (Corrigan et al., 2026; O’Nions et al., 2025).
2. ADHD Care Deserves to Extend Beyond Productivity
The research supports a broader clinical conversation: safety, mental health, substance use, physical health, and the practical ability to obtain care belong alongside attention and task completion.
Work performance alone is an inadequate measure of whether someone’s health needs are being met (Corrigan et al., 2026).
3. Medication Decisions Should Be Collaborative, Not Fear-Driven
The mortality findings are relevant to shared decision-making, but they are not a reason to start, stop, or change medication without discussing individual circumstances with a prescriber.
Potential benefits, side effects, cardiovascular history, treatment response, and personal preferences all matter. Lower observed mortality does not establish that every person should take medication; cardiovascular associations do not establish that every person should avoid it (Corrigan et al., 2026; Zhang et al., 2024).
4. Make the Care Plan Easier to Carry Out
A practical implication of the review is to reduce the administrative demands of health maintenance. Possible supports include scheduling follow-ups before leaving an appointment, using reminders, requesting written instructions, and arranging help with appointment or prescription logistics.
These are implementation suggestions—not interventions proven by this meta-analysis to reduce mortality. Their rationale is the review’s identification of organization and health-care engagement as possible points of vulnerability (Corrigan et al., 2026).
5. Co-Occurring Distress Deserves Its Own Treatment
Persistent depression, problematic substance use, or thoughts of suicide should not be dismissed as merely part of ADHD.
The mortality findings reinforce the importance of comprehensive assessment rather than assuming that treatment of core ADHD symptoms addresses every relevant risk (Corrigan et al., 2026).
6. Asking for Help Is Not a Weakness
Corrigan et al. (2026) discuss structural disadvantage, stigma, and barriers to inclusive care. A prevention-oriented response should therefore ask what clinicians, employers, health systems, and communities can change, not place the entire burden on ADHDers to navigate inaccessible systems.
Conclusion: A Public-Health Signal, Not a Prognosis
The emerging literature supports three distinct propositions: ADHD is associated with elevated mortality in studied populations; medication use is associated with lower all-cause mortality among people with ADHD; and neither association, by itself, establishes causation or predicts an individual’s lifespan (Corrigan et al., 2026).
The ethical challenge is to communicate the seriousness of these findings without converting uncertainty into fear. Mortality research should broaden the goals of ADHD care; from symptom reduction alone to accessible, sustained support for health and safety across the lifespan.
This article provides educational analysis and is not individualized medical advice.
APA Reference List
Corrigan, L., Heywood, L., Stewart, G. R., O’Nions, E., Shelford, H., Stott, J., & John, A. (2026). Mortality among people with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. JAMA Network Open, 9(10), Article e2639448. doi:10.1001/jamanetworkopen.2026.39448
Li, L., Zhu, N., Zhang, L., Kuja-Halkola, R., D’Onofrio, B. M., Brikell, I., Lichtenstein, P., Cortese, S., Larsson, H., & Chang, Z. (2024). ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA, 331(10), 850–860. doi:10.1001/jama.2024.0851
O’Nions, E., El Baou, C., John, A., Lewer, D., Mandy, W., McKechnie, D. G. J., Petersen, I., & Stott, J. (2025). Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: Matched cohort study. The British Journal of Psychiatry, 226(5), 261–268. doi:10.1192/bjp.2024.199
Zhang, L., Li, L., Andell, P., Garcia-Argibay, M., Quinn, P. D., D’Onofrio, B. M., Brikell, I., Kuja-Halkola, R., Lichtenstein, P., Johnell, K., Larsson, H., & Chang, Z. (2024). Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry, 81(2), 178–187. doi:10.1001/jamapsychiatry.2023.4294
